Breaking Finance News

NewLink Genetics (NYSE:NLNK) target price lowered to $8.00, reported today by Robert W. Baird

Having a price of $6.61, NewLink Genetics (NYSE:NLNK) traded -0.90% lower on the day. With the last close down -4.90% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. NewLink Genetics has recorded a 50-day average of $10.53 and a two hundred day average of $11.52. Volume of trade was down over the average, with 931,308 shares of NLNK changing hands under the typical 2,532,910

NewLink Genetics (NYSE:NLNK) had its price target dropped to $8.00 by Robert W. Baird in an issued report announced 06/08/2017. The dropped price target suggests a potential upside of 0.21% from the company's most recent close.

On 05/05/2017, Cantor Fitzgerald released a statement on NewLink Genetics (NYSE:NLNK) upped the target price from $0.00 to $32.00 that suggested an upside of 0.89%.

Performance Chart

NewLink Genetics (NYSE:NLNK)

With a total market value of $0, NewLink Genetics has with a one year low of $5.90 and a one year high of $25.17 .

A total of 6 brokerages have issued a ratings update on NewLink Genetics. Two brokerages rating the company a strong buy, three brokerages rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $34.33.

General Company Details For NewLink Genetics (NYSE:NLNK)

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.